Remote review and consults
For hospitals and pathology practices needing to maintain routine services and consultations, we’ll rapidly stand up an instance of Concentriq Dx for remote, image-based end-to-end workflows.
On April 24, the FDA issued guidance on on a policy to help expand the availability of remote digital pathology devices in an effort to facilitate pathology services during COVID-19. Proscia has accordingly made available Concentriq Dx for remote use in clinical practice in the United States. Concentriq Dx is CE-marked for use in primary diagnosis in Europe.
On March 26, the CMS granted a waiver allowing pathologists to work remotely, outside of CLIA-licensed facilities, during these times. This waiver gives laboratories the regulatory flexibility to maintain operations with digital pathology.
Education and collaboration
We’re providing a limited use edition of Concentriq, free of charge, to enable sharing of digital teaching sets, real-time collaborative sessions, and exchange of research data.
We'll work to help you quickly implement digital pathology to tackle this challenge together.